"We believe the data presentation could include the PK data and data from the placebo-treated patients, Janney analyst Yun Zhong said in a recent note.
If Kaufman presents positive data on placebo controlled patients, could we reach our tipping point?? Or will we need to show more....
I agree the Market acceptance phase will come long before approval. Examples SAGE and Arrowhead. Soon many will see the potential future revenues as nearly "fiat accompli" and Anavex will be rapidly revalued accordingly. A collaboration with a BP will greatly speed this process, certainly the Science is not lost on them especially after the recent revelations that the preclinical biomarkers translated in the human trials for RETT. There should be little doubt that those would translate in other neurodevelopmental indications as well.
News 
Market Data 
Discover 
AI
